Opinion: BC needs to step up and provide access to long-acting HIV medications

I have been living with HIV (Human Immunodeficiency Virus) for 38 years, and have had an undetectable viral load (less than 40 copies/mL) since 1998. Both of these facts are possible because of activism, community care, and HIV medications.

BC has been my home for 28 years. I chose to live here because this province, and the BC Centre for Excellence in HIV/AIDS (BC-CfE), has led the charge in HIV treatment innovation throughout the epidemic: the development of HIV triple-drug combination therapy called “highly active antiretroviral therapy” (HAART), and for developing the Treatment as Prevention Strategy (TasP), which has linked patients to care, treatment and prevention. Working together with numerous community organizations, the BC Centre for Excellence in HIV/AIDS has saved the lives of thousands of HIV-positive people and reduced new HIV infections.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below

Laboratory Order Forms

Start typing and press enter to search